AstraZeneca Responds to Claims Asserted in Seroquel Class Action Suit

ORLANDO, Fla. - The manufacturer of Seroquel refuted claims by plaintiffs seeking to establish a nationwide class for individuals who ingested the atypical antipsychotic and allegedly developed diabetes or experienced symptoms commonly associated with the disease. Susan Zehel-Miller, et al., v. AstraZeneca, PLC., No. 03-CV-1258 (M.D. Fla., Orlando Div.).

AstraZeneca's Oct. 20 Answer and Affirmative Defenses states that the plaintiffs failed to state a claim upon which relief can be granted and that the proposed class fails to satisfy the requirements of Rule 23.

'Plaintiffs, or their physicians, were aware or should have been aware of any potential hazards reported …